Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. - Wikidata - awgldk - TriplyDB

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

http://www.wikidata.org/entity/Q34596741

about

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors Expression of recombinant antibodies.Current treatment options of T cell-associated immunotherapy in multiple myeloma.Recent advances of bispecific antibodies in solid tumors.Targeting Malignant Brain Tumors with Antibodies.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.

P2860

Q33929184-5C3EC7C6-DF2D-4778-965A-5DC8090CBD0F Q34548319-98E36F74-2188-4583-A131-FA65233F16D5 Q36367252-CAB6C091-94AE-4B44-B8A7-D5542A39FB66 Q38126016-C7C0ED97-1676-437B-A5F2-56E4D1F70C47 Q39102170-A611F97B-D3D2-41FE-A07B-1E899F62A643 Q41696278-8902C9EA-254A-41C4-9928-FBFAF0261660 Q42267793-CA21196A-FD04-496A-86AD-B24BE736AEC0 Q47103332-C95970F8-1211-436B-BE96-ADDB8305A903

P2860

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

http://www.wikidata.org/entity/Q34596741

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting and killing of gliob ...... ed with bispecific antibodies.

@ast

Targeting and killing of gliob ...... ed with bispecific antibodies.

@en

Targeting and killing of gliob ...... ed with bispecific antibodies.

@nl

type

label

Targeting and killing of gliob ...... ed with bispecific antibodies.

@ast

Targeting and killing of gliob ...... ed with bispecific antibodies.

@en

Targeting and killing of gliob ...... ed with bispecific antibodies.

@nl

prefLabel

Targeting and killing of gliob ...... ed with bispecific antibodies.

@ast

Targeting and killing of gliob ...... ed with bispecific antibodies.

@en

Targeting and killing of gliob ...... ed with bispecific antibodies.

@nl

P1433

Q34596741-56761375-C54C-4284-A4E8-C818ACCDD081

P1476

Q34596741-95F12E13-8DD3-4C82-94E0-9B54A6E24CA1

P2093

Q34596741-06972F9E-E2DE-44F7-861F-A0281C3258C5

Q34596741-10D8DB98-BDA4-4E49-BCCE-4D52D5475663

Q34596741-1A4E6BC0-CDDE-432B-BC14-7EC9E6754AF8

Q34596741-59CA2AD7-E8BF-4E22-8A60-2E564B95FF15

Q34596741-66AEEB9F-D928-4ED5-B4E2-86742633304E

Q34596741-B325010D-C27F-4411-9378-5D438C1D0170

P2860

Q34596741-0566D812-853A-43C1-9718-4BAE1FBE0046

Q34596741-0D3B8B2C-405F-422C-A4F5-8240B27C1EFA

Q34596741-0F696D3F-BA38-4DD8-804A-099698DDD23F

Q34596741-10725F98-E167-4342-A3FF-0C986C9D85AE

Q34596741-1F023855-91F1-46BA-80F4-8B11A8058A2B

Q34596741-245252DE-E2ED-4D09-8BC3-20D835505F64

Q34596741-2A94810C-009C-48AC-A88D-00A7A3BA88B0

Q34596741-2AD02465-9F58-433B-ADC9-FB26AC4F3249

Q34596741-3172CC5F-C45C-4157-9A8D-95063F0DB4AB

Q34596741-33C8C4FC-6117-4130-9703-879DE7808598

P2888

Q34596741-2955E8F5-2B58-44D4-B8FB-125DC4794D27

P304

Q34596741-D8E2F77D-A93A-48B7-9DEB-E7408B59F5AD

P31

Q34596741-9646A9F3-67EA-4137-B234-8851125CD618

P356

Q34596741-AF548D67-1693-4F82-A88B-7AF495511A4F

P407

Q34596741-FBD84DEE-E528-4B99-8A0B-5EDCA05E929F

P478

Q34596741-1A884BDE-12C2-4A51-BF2C-2825B4BF5799

P577

Q34596741-6D6EFAC8-D231-4988-AB87-0D7583887A6F

P5875

Q34596741-85AB0373-14B0-4A56-921C-6B8CC53D66AE

P6179

Q34596741-182AE4E0-B33F-487B-96A0-5E72885EAE04

P698

Q34596741-081AF3F3-704F-44FA-AD48-F45F832130CD

P921

Q34596741-A32B759F-6514-4188-A598-D264A1CB8E2D

P932

Q34596741-2FEA4105-B0B4-402F-9B77-515E2101130B

P356

1471-2407-13-83

P1433

P1476

Targeting and killing of gliob ...... ed with bispecific antibodies.

@en

P2093

Archana Thakur

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Barger

http://www.w3.org/2001/XMLSchema#string

Ian M Zitron

http://www.w3.org/2001/XMLSchema#string

Lawrence G Lum

http://www.w3.org/2001/XMLSchema#string

Oxana Norkina

http://www.w3.org/2001/XMLSchema#string

Sandeep Mittal

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective identification of tumorigenic breast cancer cells

Mutation and functional analysis of IL-13 receptors in human malignant glioma cells

Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells

Mutation and Functional Analysis of IL-13 Receptors in Human Malignant Glioma Cells

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Cancer therapy with bispecific antibodies: Clinical experience.

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.

P2888

1471-2407-13-83

P304

83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-83

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235714856

http://www.w3.org/2001/XMLSchema#string

P6179

1001768109

http://www.w3.org/2001/XMLSchema#string

P698

23433400

http://www.w3.org/2001/XMLSchema#string

P921

P932

3599512

http://www.w3.org/2001/XMLSchema#string